Annual General Meeting of Eckert & Ziegler SE Approves Split-Off of Pentixapharm AG – Biotech Investments

Berlin, June 26, 2024. The Annual General Meeting of Eckert & Ziegler SE (ISIN DE0005659700) today resolved to split-off Pentixapharm AG from Eckert & Ziegler SE and to distribute a dividend of EUR 0.05 per share for the 2023 financial year.

As in the previous year, the Annual General Meeting was held as an in-person event at Eckert & Ziegler SE’s headquarters in Berlin. A total of 57.6% of the company’s share capital was represented.

The detailed voting results of the Annual General Meeting and the presentation by the Chairman of the Executive Board are published on the Eckert & Ziegler SE website:
https://www.ezag.com/home/investors/annual_general_meeting/

About Eckert & Ziegler
Eckert & Ziegler SE with more than 1.000 employees is a leading specialist for isotope-related components in nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
Contributing to saving lives.

Your contact:
Eckert & Ziegler SE, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de, www.ezag.com